Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes

Life Sciences

Volumn 89, Issue 17-18, 2011, Pages 662-670

  Tajima, Atsushi ^a   Hirata, Takashi ^a   Taniguchi, Kazuo ^a   Kondo, Yukiko ^a   Kato, Sota ^a   Saito Hori, Masako ^a   Ishimoto, Tsuyoshi ^a   Yamamoto, Koji ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dipeptidyl peptidase IV; High fat diet; Incretin; Insulin; Oral glucose tolerance test; Pancreatic islet; Streptozotocin

Indexed keywords

4 FLUORO 1 [((2 HYDROXY 1,1 DIMETHYLETHYL)AMINO)ACETYL] PYRROLIDINE 2 CARBONITRILE MONOBENZENESULFONATE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; METFORMIN; STREPTOZOCIN; TS 021; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES;

ANIMALS; BENZENESULFONATES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DRUG SYNERGISM; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; PYRROLIDINES;

MUS;

EID: 80053568265     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.08.005     Document Type: Article

References (33)

1. B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, and P.A. Jansson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875 (Pubitemid 41094285)
2. B. Ahrén, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 2004 2874 2880 (Pubitemid 39565052)
3. B. Ahrén Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin Vasc Health Risk Manag 4 2008 383 394 (Pubitemid 351711966)
4. J. Buteau, S. Foisy, C.J. Rhodes, L. Carpenter, T.J. Biden, and M. Prentki Protein kinase Cς activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation Diabetes 50 2001 2237 2243 (Pubitemid 33641907)
5. S.L. Conarello, Z. Li, J. Ronan, R.S. Roy, L. Zhu, and G. Jiang Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc Natl Acad Sci U S A 100 2003 6825 6830 (Pubitemid 36666664)
6. C.F. Deacon, T.E. Hughes, and J.J. Holst Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 47 1998 764 769 (Pubitemid 28201806)
7. R.A. Defronzo Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
8. M.Y. Donath, and P.A. Halban Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications Diabetologia 47 2004 581 589 (Pubitemid 38491259)
9. A. Duttaroy, F. Voelker, K. Merriam, X. Zhang, X. Ren, and K. Subramanian The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats Eur J Pharmacol 650 2010 703 707
10. H. Fukushima, A. Hiratate, M. Takahashi, A. Mikami, M. Saito-Hori, and E. Munetomo Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors Bioorg Med Chem 16 2008 4093 4106 (Pubitemid 351484008)
11. Y. Furuta, M. Horiguchi, E. Sugaru, M. Ono-Kishino, M. Otani, and M. Sakai Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice Diabetes Obes Metab 12 2010 421 430
12. S.A. Hinke, K. Kühn-Wache, T. Hoffmann, R.A. Pederson, C.H. McIntosh, and H.U. Demuth Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1 Biochem Biophys Res Commun 291 2002 1302 1308 (Pubitemid 34694333)
13. H. Hui, A. Nourparvar, X. Zhao, and R. Perfetti Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 2003 1444 1455 (Pubitemid 36432086)
14. International Diabetes Federation IDF diabetes atlas 4th edition 2009 http://www.idf.org/diabetesatlas
15. 2+ release in INS-1 pancreatic β-cells J Physiol 536 2001 375 385 (Pubitemid 32976119)
16. Y. Kashima, T. Miki, T. Shibasaki, N. Ozaki, M. Miyazaki, and H. Yano Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion J Biol Chem 276 2001 46046 46053
17. M. Kirby, D.M. Yu, S. O'Connor, and M.D. Gorrell Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition Clin Sci (London) 118 2010 31 41
18. J.L. Leahy, I.B. Hirsch, K.A. Peterson, and D. Schneider Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus J Clin Endocrinol Metab 95 2010 4206 4216
19. X. Liu, N. Harada, S. Yamane, L. Kitajima, S. Uchida, and A. Hamasaki Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice Life Sci 84 2009 876 881
20. J. Luo, J. Quan, J. Tsai, C.K. Hobensack, C. Sullivan, and R. Hector Nongenetic mouse models of non-insulin-dependent diabetes mellitus Metabolism 47 1998 663 668 (Pubitemid 28265168)
21. A. Maida, B.J. Lamont, X. Cao, and D.J. Drucker Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice Diabetologia 54 2010 339 349
22. E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, and E. Pierazzuoli Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 24 2001 489 494 (Pubitemid 32198418)
23. D.R. Matthews, C.A. Cull, I.M. Stratton, R.R. Holman, and R.C. Turner UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group Diabet Med 15 1998 297 303
24. E.M. Migoya, R. Bergeron, J.L. Miller, R.N. Snyder, M. Tanen, and D. Hilliard Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1 Clin Pharmacol Ther 88 2010 801 808
25. J. Mu, A. Petrov, G.J. Eiermann, J. Woods, Y.P. Zhou, and Z. Li Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur J Pharmacol 623 2009 148 154
26. J.A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, and F.C. Lynn Dipeptidyl peptidase IV inhibitor treatment stimulates L-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741 750 (Pubitemid 36323582)
27. R.E. Pratley, and A. Salsali Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes Curr Med Res Opin 23 2007 919 931 (Pubitemid 46631495)
28. A. Tahara, A. Matsuyama-Yokono, R. Nakano, Y. Someya, M. Hayakawa, and M. Shibasaki Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice Eur J Pharmacol 605 2009 170 176
29. A. Tajima, K. Yamamoto, A. Kozakai, L. Okumura-Kitajima, Y. Mita, and K. Kitano (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}- pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor Eur J Pharmacol 655 2011 99 107
30. Q. Wang, L. Li, E. Xu, V. Wong, C. Rhodes, and P.L. Brubaker Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells Diabetologia 47 2004 478 487 (Pubitemid 38491244)
31. X. Wang, J. Zhou, M.E. Doyle, and J.M. Egan Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism Endocrinology 142 2001 1820 1827 (Pubitemid 32405938)
32. N. Yasuda, T. Inoue, T. Nagakura, K. Yamazaki, K. Kira, and T. Saeki Enhanced secretion of glucagon-like peptide 1 by biguanide compounds Biochem Biophys Res Commun 298 2002 779 784 (Pubitemid 35356808)
33. N. Yasuda, T. Inoue, T. Nagakura, K. Yamazaki, K. Kira, and T. Saeki Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats J Pharmacol Exp Ther 310 2004 614 619 (Pubitemid 38988906)